Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials.
about
HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory DiseasesWill testosterone replacement therapy become a new treatment of chronic heart failure? A review based on 8 clinical trialsPotential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?New and emerging HDAC inhibitors for cancer treatmentNeuronal-specific deficiency of the splicing factor Tra2b causes apoptosis in neurogenic areas of the developing mouse brainEpigenetic polypharmacology: from combination therapy to multitargeted drugsA Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC.Histones: Controlling Tumor Signaling CircuitryGlycolysis-dependent histone deacetylase 4 degradation regulates inflammatory cytokine production.Randomized phase II study of 5-fluorouracil hepatic arterial infusion with or without antineoplastons as an adjuvant therapy after hepatectomy for liver metastases from colorectal cancer.Gcn5 Modulates the Cellular Response to Oxidative Stress and Histone Deacetylase Inhibition.Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acidsEpigenetically maintained SW13+ and SW13- subtypes have different oncogenic potential and convert with HDAC1 inhibition.Up-regulation of HDAC9 promotes cell proliferation through suppressing p53 transcription in osteosarcoma.Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells.Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinomaInfluence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.Targeting of histone deacetylases to reactivate tumour suppressor genes and its therapeutic potential in a human cervical cancer xenograft model.MicroRNA let-7 downregulates STAT3 phosphorylation in pancreatic cancer cells by increasing SOCS3 expression.A novel method for isolation of histones from serum and its implications in therapeutics and prognosis of solid tumoursHistone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts.Epigenetic alterations in osteosarcoma: promising targets.Epigenetic pathway targets for the treatment of disease: accelerating progress in the development of pharmacological tools: IUPHAR Review 11.Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.Histone deacetylase inhibitors in oral squamous cell carcinoma treatment.Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases.Emerging approaches for histone deacetylase inhibitor drug discovery.Marked for death: targeting epigenetic changes in cancer.Histone deacetylase inhibitors as immunomodulators in cancer therapeutics.Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAsNuclear phosphoinositide regulation of chromatin.Epigenetics and Cancer Stem Cells: Unleashing, Hijacking, and Restricting Cellular Plasticity.Novel histone deacetylase inhibitor AR-42 exhibits antitumor activity in pancreatic cancer cells by affecting multiple biochemical pathways.Reversible acetylation regulates vascular endothelial growth factor receptor-2 activity.Transmembrane voltage potential of somatic cells controls oncogene-mediated tumorigenesis at long-range.Nuclear expression of histone deacetylases and their histone modifications predicts clinical outcome in colorectal cancer.Metabolic inhibitors accentuate the anti-tumoral effect of HDAC5 inhibition.Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay.Perfluorinated HDAC inhibitors as selective anticancer agents.Epigenetic alterations are associated with monocyte immune dysfunctions in HIV-1 infection.
P2860
Q26739120-5EEF332A-04DF-4E92-A945-A1315D0153E9Q26750979-F60E6F45-81C9-41CC-8E98-860B0AD559A9Q26771601-3A2B7191-C335-44A2-85EB-2AAB8454C03CQ27022413-06EA5675-CD20-4D05-9C1E-6B18D8F55FEFQ27321571-2C8A9553-B571-46C7-99D4-A005877E609DQ28067666-68EF46D8-F348-4990-B6CF-72688FA3E7BCQ33689457-E15D9F85-9EA0-4699-8298-F1B5047F7212Q34109472-1433596E-F55C-43EC-AECD-02CB58FED2FEQ34428648-828C5984-3377-4C9E-ADB4-720564010318Q35195934-4A8EB39A-CAC0-4DC2-8435-158AB05666B6Q35574284-7612E479-CAD6-4A3C-82DB-0997E2227D88Q35613117-8B05A3B6-2D6F-48A5-958B-A1F8E181315CQ36020172-2D93BFB8-827B-41D1-AA47-E611F43BF925Q36047009-A8D94125-0CDB-447C-B68B-BBA4A378FDBEQ36446188-162FC3B6-8F68-4DC1-90B5-0E2956082AA5Q36605917-AE16B8AE-5FD6-4822-BE30-597088B662E5Q37260402-5CFCD475-58CE-459E-885D-64B8708B268BQ37325233-EF07BD7B-624E-4688-BB5D-853A8134FFAAQ37678651-C48D9BF5-1E29-4636-82EE-A10F3A1894DBQ37728595-6CB8C068-8DC7-44C4-905D-477AAF09BB1EQ37745937-F6F0A62C-B9BB-453C-A98D-0221B1BF0E9CQ38185555-60078D97-CB56-4D36-9D00-BBFB9A581883Q38233723-87471B9B-D080-4C17-9031-D0C813F53B5AQ38240733-166A3B05-A329-4A4C-AF5A-A5B58006A76EQ38248710-C4A9E451-6165-463A-8682-E6DC46F72D09Q38264859-5C042DDF-F1F5-40E5-92CA-3CD86ACF3600Q38431356-6E271590-28E3-4985-9677-FD632313B798Q38747872-4C412A2C-A017-46BF-8383-B1F2DAAD4810Q38763747-3D8CA59D-3039-4851-93ED-B590BA1A4333Q38777547-621BA849-2166-462F-86A3-805EDD07315AQ39159757-04AD678F-E9C5-4404-A4AC-4A338B15DA66Q39441283-C32691C4-29BF-426D-A59E-470D03BC9326Q40084337-A987E977-4BC5-4B3C-8FB7-8CC68FF868ADQ42647940-D1E31368-1002-4C8C-9B6D-B69B3B688A7CQ42739122-C3F5AB3E-7370-439C-86B5-96956E70FC8EQ43448263-0158914B-FBAD-4352-B9AB-99AE7F9BE77BQ46382193-063D19EB-A222-40D9-87B7-F28AF1BC3CC7Q47645910-61837777-F2D6-487D-991A-CFDEBE4C77C0Q50089128-192A07D1-EC98-4779-92DA-58691E991D4DQ54679094-1DD3BA55-6EFC-4BA6-B08B-DB6CEE0C3F34
P2860
Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Effects of treatment with hist ...... w based on 30 clinical trials.
@en
type
label
Effects of treatment with hist ...... w based on 30 clinical trials.
@en
prefLabel
Effects of treatment with hist ...... w based on 30 clinical trials.
@en
P2093
P2860
P356
P1433
P1476
Effects of treatment with hist ...... w based on 30 clinical trials.
@en
P2093
Tianzhu Qiu
Tongshan Wang
Yongqian Shu
P2860
P304
P356
10.2217/FON.12.173
P407
P577
2013-02-01T00:00:00Z